Science + Engineering
Nano Biosols Ltd was founded in 2014 after the founder, Adrian Walsh, had spent many years helping develop the core technology at the University of Liverpool. The company manufactures and supplies biologically active colloidal metal nanoparticles to academic and commercial customers. The applications for these materials are in biomedical research and as components in in-vitro diagnostic kits.
The first generation of biologically functionalised gold nanoparticles was developed as a tool in life science research, mainly in microscopy. The second generation nanoparticles were used as components in lateral flow in-vitro diagnostic kits, where they produce a macroscopic red signal confirming the result of a test. It is predicted that the third generation of gold nanoparticles will feature as theranostics i.e. as therapeutic and diagnostic agents in the developing field of nanomedicine. It is assumed that the next generation will be multi-modal in that they can be targeted, imaged and deliver a therapeutic action.